Madrigal Pharmaceuticals (MDGL) Competitors

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Is MDGL or DRNA more profitable?

Madrigal Pharmaceuticals has a net margin of 0.00% compared to Dicerna Pharmaceuticals' net margin of -64.53%. Madrigal Pharmaceuticals' return on equity of -71.78% beat Dicerna Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	N/A	-71.78%	-53.25%
Dicerna Pharmaceuticals	-64.53%	-103.08%	-16.58%

Does the media refer more to MDGL or DRNA?

In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than Dicerna Pharmaceuticals. MarketBeat recorded 5 mentions for Madrigal Pharmaceuticals and 0 mentions for Dicerna Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.90 beat Dicerna Pharmaceuticals' score of 0.00 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Madrigal Pharmaceuticals	Positive
Dicerna Pharmaceuticals	Neutral

Which has higher valuation and earnings, MDGL or DRNA?

Dicerna Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	N/A	N/A	-$373.63M	-$25.08	-12.64
Dicerna Pharmaceuticals	$164.31M	18.17	-$112.75M	-$1.63	-23.45

Do institutionals & insiders hold more shares of MDGL or DRNA?

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.9% of Dicerna Pharmaceuticals shares are owned by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 10.2% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more volatility & risk, MDGL or DRNA?

Madrigal Pharmaceuticals has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Do analysts prefer MDGL or DRNA?

Madrigal Pharmaceuticals presently has a consensus price target of $347.33, indicating a potential upside of 9.54%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Madrigal Pharmaceuticals is more favorable than Dicerna Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Dicerna Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the MarketBeat Community believe in MDGL or DRNA?

Madrigal Pharmaceuticals received 3 more outperform votes than Dicerna Pharmaceuticals when rated by MarketBeat users. Likewise, 67.70% of users gave Madrigal Pharmaceuticals an outperform vote while only 61.02% of users gave Dicerna Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Madrigal Pharmaceuticals	Outperform Votes 457 67.70%	Underperform Votes 218 32.30%
Dicerna Pharmaceuticals	Outperform Votes 454 61.02%	Underperform Votes 290 38.98%

Summary

Madrigal Pharmaceuticals beats Dicerna Pharmaceuticals on 12 of the 17 factors compared between the two stocks.